Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?

Nature Clinical Practice Endocrinology & Metabolism volume 1, pages 70–71 (2005)Cite this article

boxed-textKendall DM et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083–1091

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Drucker DJ (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26: 2929–2940

    Article  CAS  Google Scholar 

  2. Buse JB et al. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628–2635

    Article  CAS  Google Scholar 

  3. Defronzo RA et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092–1100

    Article  CAS  Google Scholar 

  4. Heine RJ et al. (2005) Comparison of exenatide and insulin glargine in MET and SU-treated patients with type 2 diabetes: exenatide achieved equivalent glycemic control, with weight reduction and less nocturnal hypoglycemia [abstract]. In Program and Abstracts of the 65th Scientific Sessions of the American Diabetes Association, 2005 June 10–14, San Diego

    Google Scholar 

  5. Gedulin BR et al. (2005) Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48: 1380–1385

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine and the Director of the Banting and Best Diabetes Center in the Department of Medicine, Toronto General Hospital, University of Toronto, Canada

    Daniel J Drucker

Authors
  1. Daniel J Drucker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J Drucker.

Ethics declarations

Competing interests

D. Drucker is a member of the Scientific Advisory Board for Amylin Pharmaceuticals and a consultant to Amylin and Eli Lilly Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Drucker, D. Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?. Nat Rev Endocrinol 1, 70–71 (2005). https://doi.org/10.1038/ncpendmet0026

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0026

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing